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Summary. Helper T-lymphocyte precursor (HTLp) frequency
from 19 allogeneic bone marrow donors was tested to detect
weak antigenic differences with the recipient, and then
compared to the outcome. HTLp frequency was estimated in
limiting dilution cultures, and HLA-DR and CD 80 expres-
sion by stimulating cells was measured by flow cytometry.
12/19 patients experienced acute graft-versus-host disease
(aGVHD) grade II–IV. A good correlation was found between
high pretransplant HTLp frequency and grade II–IV aGVHD
(median: 1/55848 PBMNC for II–IV GVHD versus 1/
184346 for 0–I GVHD; P ¼ 0·008). Sensitivity was 82%,
specificity 63%, negative predictive value 71% and positive
predictive value 75%. Long-term survivors also had a lower
HTLp median frequency (1/143354) when compared
with patients who died as a result of the transplant
procedure (1/22100, P <0·001). No correlation was found
between HTLp frequency and HLA-DR or CD80 expression
by patient’s cells. We conclude that HTLp frequency
estimation can predict, although poorly, acute GVHD risk
and long-term survival.
Keywords: helper T-lymphocyte precursor frequency,
acute graft-versus-host disease prediction, bone marrow
transplantation, long-term survival prediction.
Despite recent progress in compatibility tests performed
before bone marrow transplantation (BMT), it is still difficult
to predict graft-versus-host disease (GVHD). Many allo-
grafted patients suffer from this wide immune reaction.
Direct mortality or severe morbidity post transplantation
may be related to GVHD in 25% of patients (Ferrara & Deeg,
1991; Hansen et al, 1995). Therefore much has been done to
avoid and treat this syndrome, using immunological,
epidemiological and pharmacological approaches.
The risk factors for developing GVHD are well known.
They include HLA disparities between donor and recipient,
older age, female donor with male recipient, an unrelated
donor and previous viral infections (van Bekkum, 1991;
Kelemen et al, 1993; Kalhs, 1993; Appleton & Sviland,
1993; Aschan et al, 1994). However, even when the risk of
developing a GVHD is small, it remains a problem when the
graft has not been T-cell depleted.
Thus, in vitro functional tests have been designed to predict
the risk for GVHD for each donor–recipient pair. The mixed
lymphocyte reaction (MLR) has been widely used, but
analyses on large numbers of patients did not show any
correlation between a high response index and GVHD
occurrence (Segall et al, 1996; Mickelson et al, 1996).
Recently, several groups have tested donor immunological
response to patient antigens in limiting dilution assays
(LDA). These quantitative assays have been designed to
estimate cytotoxic or helper T lymphocyte precursor
frequencies (CTLp, HTLp). The predictive value obtained of
tests seemed better than those of MLR. Host-reactive
precursors frequency was often related to HLA or minor
histocompatibility mismatches (Theobald et al, 1992;
Schwarer et al, 1994; Spencer et al, 1995a, b; Bunjes et al,
1995; Potolicchio et al, 1996; Keever-Taylor et al, 1997; van
der Meer et al, 1997).
On the basis of these encouraging results, we decided to
test allogeneic bone marrow adult donor HTLp frequency.
As class II HLA molecules are essential for antigen
presentation to CD4þ Tcells, their expression on a patient’s
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peripheral blood mononuclear cells (PBMNC) was measured
by flow cytometry. CD 80 (B7.1) molecule expression was
also measured to investigate the co-signalling capacity of
these cells. The results were then compared with clinical
events.
MATERIALS AND METHODS
Patients. We studied bone marrow donor alloreactivity to
the antigens of 19 patients. These patients were allografted
at our centre between 1989 and 1996. The median age at
transplant was 45 years (range 24–59); donor median age
was 38 (range 30–46). Donors were HLA-identical siblings
(17) or volunteer unrelated donors (two). Diagnoses were
severe aplastic anaemia (one), acute lymphoblastic leukae-
mia (two), chronic lymphocytic leukaemia (two), acute
myeloid leukaemia (one), chronic myeloid leukaemia (five),
non-Hodgkin’s lymphoma (four), myelodysplastic syndrome
(one) and multiple myeloma (three). Four patients had
advanced disease (later than first remission or acute-phase
CML) and 15 had standard-risk disease (first complete
remission or first chronic phase). None of the grafts was T-
cell depleted. Conditioning regimen before BMT and other
patient characteristics are shown in Table I. Acute GVHD
was graded according to established criteria (Przepiorka et al,
1995).
HLA typing. Class I HLA molecules were serologically
determined for all donor–recipient pairs. Class II molecules
or genes were typed with the following methods: serology
(patients 3, 5, 8, 15, 16 and 18); PCR-RFLP (patients 1, 3, 9,
14, 15, 17 and 18); reverse dot blot (patients 1, 2, 4, 6, 10,
11, 12, 13, 16 and 19), and PCR-SSP (patients 6, 10, 11, 12,
16, 18 and 19). For 10 patients a combination of several of
these methods was necessary to reach a high resolution
typing. For patients 5 and 8, class II HLA molecules were
typed only by serology. Patient 3 had a HLA-DR 6 allelic
difference with his unrelated donor detected by RFLP.
Harvesting and cryopreservation of donor and patient PBMNC.
Heparinized or citrated blood from patients and their bone
marrow donor was harvested within the 2 weeks preceding
BMT, separated on Ficoll-Hypaque (density ¼ 1·077, Inter-
national Medical, Belgium), washed three times in
RPMI 1640 medium (Gibco) and cryopreserved in liquid
nitrogen at 5 · 106 cells/ml in RPMI 1640 containing
20% heat-inactivated normal AB human pooled serum,
glutamin (1·5 mM), penicillin (50 U/ml), streptomycin
(50 mg/ml), gentamycin (500 mg/ml) (all from Gibco) and
10% dimethylsulphoxide (Merck, Belgium).
Maintenance of IL-2-sensitive cell line A9.12. The A9.12 cell
line was cultivated in RPMI 1640 supplemented with 10%
heat-inactivated fetal calf serum (Gibco), glutamine
(1·5 mM), hepes buffer (10 mM), sodium pyruvate (2 mM),
2-mercaptoethanol (5 · 10¹5 M), penicillin (50 U/ml), strep-
tomycin (50 mg/ml), and gentamycin (500 mg/ml). Recombi-
nant human IL-2 (Eurocetus) was added to reach a final
concentration of 100 IU/ml. Cells were divided every 2 or 3 d
Table I. Patient diagnoses and conditioning.
UPN Patient sex Donor sex Patient age Donor age Donor type Diagnosis Conditioning
1 M M 53 47 ID ALL (s) 1
2 M F 33 30 ID NHL (s) 1
3 M F 25 33 MUD CML (a) 1
4 F M 47 46 ID NHL (s) 1
5 F M 49 59 ID NHL (a) 2
6 M F 54 53 ID MM (s) 3
7 M M 48 45 ID CLL (s) 1
8 M M 49 46 ID MM (s) 3
9 M M 45 49 ID AML (s) 1
10 M M 36 43 ID SAA (s) 4
11 F F 55 45 ID MM (s) 3
12 M M 59 52 ID CML (a) 5
13 M F 24 20 ID NHL (s) 1
14 M F 30 28 ID CML (a) 1
15 M M 41 44 ID CLL (s) 1
16 M F 45 42 ID CML (s) 1
17 M F 32 47 MUD ALL (s) 2
18 F F 53 66 ID MDS (s) 1
19 M F 43 36 ID CML (s) 1
Conditioning: 1 ¼ total body irradiation 800 cGy þ cyclophosphamide; 2 ¼ total body irradiation 1000 cGy þ cyclophosphamide; 3 ¼ total
body irradiation 800 cGy þ high-dose melphalan; 4 ¼ ATG þ cyclophosphamide; 5¼ busulphan þ cyclophosphamide. All patients received
cyclosporin A and methotrexate as GVHD prophylaxis. Diagnoses: ALL: acute lymphoblastic leukaemia; AML: acute myeloid leukaemia; CLL:
chronic lymphocytic leukaemia; CML: chronic myeloid leukaemia; MDS: myelodysplastic syndrome; MM: multiple myeloma; NHL: non-
Hodgkin’s lymphoma; SAA: severe aplastic anaemia. (s): standard risk (first chronic phase or first complete remission); (a): advanced risk (CML in
accelerated or blastic phase, second or later remission). Donor type: MUD ¼ matched unrelated donor; ID ¼ identical sibling donor.
and were not allowed to exceed the maximal concentration
of 4 · 105 cells/ml (Shih et al, 1983). This cell line was kept
in a humidified atmosphere with 5% CO2 at 378C. They were
used to detect IL-2 in HTLp supernatants 2 or 3 d after the
last culture to avoid an elevated background.
Limiting dilution assay for HTLp frequency determination. IL-2
secretion from donor lymphocytes was evaluated after in
vitro stimulation with patient peripheral blood mono-
nucleated cells (PBMNC). All cells used in the HTLp assay
were thawed on the test day and washed three times.
Responding cells from the donor were diluted to obtain a
final concentration of 8 · 104 cells/well/100 ml. These cells
were plated in round-bottom plates and serially two-fold
diluted with the last dilution at 2·5 · 103 cells/well.
Stimulating cells from the patient were irradiated (20 Gy;
rate 29·6 Gy/min, source of g radiation 137Cs) and 105 cells
in 100 ml were added to responding cells. 24 replicates of
each dilution were set up. The following controls were set up:
24 wells with stimulating cells alone for determination of
positivity threshold and 16 replicates with responding cells
alone. The stimulating capacity of patient cells was
evaluated with 16 wells containing responding cells from
two unrelated HLA-mismatched healthy volunteer controls.
The responding capacity of donor cells was evaluated with
the same controls irradiated to serve as stimulating cells.
Autologous IL-2 secretion was evaluated by culturing 16
replicates of donor or recipient PBMNC with autologous
irradiated cells.
The cultures were kept in DMEM supplemented with 10%
heat-inactivated normal AB human pooled serum, gluta-
mine (1·5 mM), penicillin (50 U/ml), streptomycin (50 mg/ml)
and gentamycin (500 mg/ml), in a humidified atmosphere
with 5% CO2 at 378C for 72 h. After 72 h, 100 ml of the
supernatant were transferred to new flat-bottom plates and
frozen at ¹708C until further analysis.
On the day of analysis, plates containing supernatants
were slowly thawed (48C for 6 h, 378C for 30 min). IL-2
growth dependent cells (A9.12 murine cell line) were
washed three times in 50 ml culture medium and starved
of IL-2 for 4–6 h. They were diluted in an enriched medium
(normal culture medium supplemented with 7 mM sodium
pyruvate and 3 mM 2-mercaptoethanol) to obtain a final
concentration of 8 · 104 cells/ml. 50 ml of this solution were
then added to HTLp supernatants. To assess A9.12 cells
responsiveness to IL-2 they were incubated in a distinct
culture plate with known amounts of rhIL-2, the concentra-
tion of which ranged from 0 to 100 IU/ml.
Culture plates were incubated in an humidified atmo-
sphere, 5% CO2 at 378C for 42 h with the last 18 h in
the presence of 3H-thymidine (74 kBq/well). Thymidine
incorporation was measured by harvesting cells to filters
and counting b radiation with a b scintillation counter
(Beckman LS 6000 SE or Topcount, Packard Instruments).
When HLA-mismatched controls were negative for IL-2
secretion, the test was considered as invalid and not included
in this study.
Antibodies. Monoclonal mouse antibodies of the following
specificity were used: HLA-DR (clone B-F1, FITC labelled,
from Serotec), CD 80 (clone L307.4, PE labelled, from Becton
Dickinson), mouse IgG1 (FITC or PE labelled, from Becton
Dickinson).
Immunofluorescence staining. On the day that the limiting
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Table II. HTLp frequency estimation and patients’ clinical evolution.
HTLp
UPN frequency¹1 CI 95% P aGVHD cGVHD Clinical outcome
3 14487 10952–19163 >0·3 IV (na) Death 22 (1)
12 15270 11701–19927 >0·7 II (na) Death 104 (2)
9 22100 16590–29440 <0·1 II - Death 277 (3)
18 38903 29595–51137 <0·1 II - Alive 753
11 54505 33125–89686 >0·95 II Limited Alive 608
15 55848 30987–100655 >0·3 II Limited Alive 841
17 65113 47156–89906 <0·1 II - Death 173 (4)
10 74657 56965–97766 >0·5 0 Limited Alive 445
1 83830 44907–156490 >0·2 0 - Alive 939
7 99031 67982–144263 >0·5 0 - Alive 885
5 118698 80310–175436 >0·3 II (na) Death 83 (1, 5)
16 124877 85320–182773 >0·5 II Limited Alive 331
8 161831 80985–323383 >0·5 0 - Alive 1166
14 206860 134933–317128 >0·5 0 Limited Alive 1131
4 276457 169256–451555 >0·2 I - Alive 243
2 277311 191959–400614 >0·1 0 - Alive 187
19 311956 162818–597699 >0·1 II Limited Alive 235
13 412343 196622–864740 >0·3 0 - Alive 334
6 414621 215431–797985 >0·9 III (na) Death 190 (1, 2, 6)
Death causes: 1: GVHD; 2: pneumonitis; 3: cerebral aspergillosis; 4: relapse; 5: haemolytic uraemic syndrome;
6: denutrition. cGVHD (na): not applicable.
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dilution assay was set up, 105 stimulating cells were
incubated with 1 mg antibody for 20 min at 48C (final
volume 110 ml). The cells were then washed twice with PBS
and analysed immediately. Isotype-specific negative controls
were performed in all experiments.
Flow cytometry. Flow cytometric assays were carried out
using a Becton Dickinson FACSCANÒ . Data were acquired
and analysed using the Cell Quest software. Surface marker
expression was analysed in the mononucleated population.
At least 104 events were analysed for each patient.
Statistical analysis. Evaluation of HTLp frequency was
obtained using the x2 minimalization for the zero term of
Poisson distribution between the number of responder cells
and the fraction of negative wells (Taswell, 1984). The result
was calculated using the GLIM software (NAG Ltd, Oxford,
U.K.). P values >0·1 were considered as fitting the single hit
kinetic from Poisson model.
In HTLp tests the threshold of positivity for IL-2 secretion
was obtained from A9.12 proliferation observed in the 24
replicates set up without responder cells as follows:
percentile 75 þ (percentile 75 ¹ percentile 25) (Barnett et
al, 1984).
Comparison between median frequency obtained in
different subgroups of patients was evaluated using the
Mann-Whitney test. Disease-free survival probability was
estimated according to Kaplan & Meier (1958). The
relationship between donor sex or disease and GVHD
occurrence or survival was tested with Fisher’s exact test
or with the chi-square test.
RESULTS
HTLp frequency as a predictive test for GVHD occurrence
Donor anti-host HTLp frequency estimation was obtained for
19 patients (Table II). The median frequency was 1/99031
(range 1/14487 to 1/414621). HTLp frequency was
compared with acute GVHD occurrence, donor and patient
CMV previous infection and survival. A statistically sig-
nificant difference was observed between patients with or
without acute GVHD grade II–IV (median 1/55848 v 1/
184346; P ¼ 0·008), and between long-term survivors and
deceased patients (median 1/143354 versus 1/22100;
P <0·001). We also observed a trend to significance when
CMV-posititve patients had a seronegative donor (median 1/
79244 v 1/276457 for pairs with both patient and donor
seropositive for CMV; P ¼ 0·09). We also correlated disease
stage (standard or advanced) and donor sex with GVHD
incidence, overal outcome and HTLp test positivity and we
did not find any significant correlation. These comparisons
are summarized in Table III.
HTLp test was considered positive when more than one
donor IL-2 secreting lymphocyte among 150 000 PBMNC
could be detected. The test showed 82% sensitivity, 63%
specificity, 75% positive predictive value and 71% negative
predictive value. When donor HTLp frequency was com-
pared with survival, we found 83% sensitivity and 85%
negative predictive value. Therefore this test could also
predict post-transplantation survival. In this series of
patients probability of disease-free survival was 0·57.
HLA-DR and CD 80 expression by stimulating cells
In 16 patients’ PBMNC, HLA-DR and CD 80 expression was
Table III. Median HTLp frequency comparison between patient subgroups.
1/HTLp 1/HTLp
Patient subgroup (median) (range) N P
aGVHD 0–I 184346 74657–412343 8 0·008
aGVHD II–IV 55848 14487–414621 11
Alive 143354 54505–412343 13 <0·001
Deceased 22100 14487–414621 6
Donor CMV¹ patient CMVþ 79244 22100–118698 6
Donor and patient CMVþ 276457 15270–412343 7 0·09
P values are obtained using the Mann-Whitney test. Median follow-up for alive patients is
20 months (range 6–39).
Table IV. Percentage of positive PBMNC stimulating cells for CD80 or
HLA-DR molecule expression.
HLA-DR positive CD80 positive 1/HTLp
UPN PBMNC (%) PBMNC (%) frequency
3 16·5 2·5 14487
12 13·6 0·46 15270
18 7·34 1·21 38903
11 23·5 7 54505
15 67·7 1·5 55848
17 10 0·16 65113
10 5·34 2·7 74657
7 38·2 4·3 99031
5 46 3 118698
16 27·5 9 124877
8 50·5 0·8 161831
14 31 0·4 206860
2 14·1 0·8 277311
19 11·4 0·7 311956
13 37·5 0·6 412343
6 22 1·1 414621
measured by flow cytometry to assess the antigen presenta-
tion and co-signalling capacity of stimulating cells. We
observed a wide range of percentages of positive cells for these
two molecules (HLA-DR: median 22·7, range 67·7–5·3;
CD 80: median 1·1, range 9–0·16) (Table IV). No correla-
tion was found between HTLp frequency and HLA-DR or
CD80 expression (Fig 1); correlation coefficients were
0·0021 and 0·0881 respectively.
DISCUSSION
Donor pretransplant HTLp frequency was performed using
an established protocol with minor modifications (Schwarer
et al, 1993) in 19 patients who received allogeneic BMT.
The first modification was the choice of IL-2-dependent
cell line for the revelation of secreted IL-2 in HTLp tests. The
A9.12 murine cell line was compared with the more usual
CTLL-2 cell line. It was found to be more sensitive and
reliable for recombinant IL-2 detection and for HTLp
supernatant screening (Winandy et al, 1998). Other
investigators also have chosen this cell line for the same
reasons (Lewalle et al, 1996; Keever-Taylor et al, 1997).
However, this cell line sometimes gave a positive signal
in negative control wells (containing only stimulating
cells) in HTLp tests. These positive values may be explained
by IL-2 secretion by stimulating cells, as reported by other
investigators (Hornick et al, 1996; Reiseater et al, 1996).
Therefore the positivity threshold for determining IL-2-
positive wells had to take these outlying values into account.
The threshold was obtained as follows: percentile 75 þ (per-
centile 75 ¹ percentile 25) from the 24 negative control
culture wells. This method enabled the positivity threshold
to be based on the median value from negative control wells,
and was less influenced by the outlying values than the more
classical method (mean þ 3 standard deviations) (Barnett
et al, 1984).
Some authors considered the HTLp test positive when they
detected more than one IL-2 secreting T cell in 100 000
PBMNC (Theobald et al, 1992; Schwarer et al, 1993, 1994).
We lowered this threshold because the majority of our
patients had a related donor, with genetical HLA identity,
and probably closer identity for minor antigens than might
be the case in unrelated donor-recipient pairs. In these
conditions donor lymphocytes showed a lower IL-2 secre-
tion. This was confirmed by our observation of seven
unrelated and three related HLA-identical healthy controls.
Median HTLp frequency was 1/104700 and 1/189500,
respectively. This observation outlined the importance of
non-HLA antigenic disparities. The majority of GVHD
patients from this series had a pretransplant HTLp frequency
>1/150000 PBMNC, probably reflecting a higher minor
antigen disparity degree between donor and recipient.
q 1999 Blackwell Science Ltd, British Journal of Haematology 105: 288–294
292 M. Winandy et al
Fig 1. Correlation between HTLp frequency
and HLA-DR or CD80 expression by patient’s
PBMNC.
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The test results were closely related with GVHD and
survival, as shown previously (Theobald et al, 1992;
Schwarer et al, 1993, 1994). However, we observed a lack
in outcome prediction for patient 6 whose HTLp test
was negative, but who died as a consequence of aGVHD
grade III and infectious complications. This fatal outcome
may be explained by the fact that multiple myeloma
patients generally have a greater risk for post-transplant
complications.
There was also a trend to an increased HTLp frequency for
CMV seropositive patients with a seronegative donor. It is
known that this virus induces the expression of viral
antigens on host cells that may constitute minor antigens
(Bostro¨m et al, 1992; Appleton & Sviland, 1993; Appleton
et al, 1995). This trend for increasing HTLp frequency in
CMV-positive recipients confirms the importance of such
antigens as stimulating allogeneic responses. We did not find
any correlation between disease stage or donor sex with the
incidence of acute GVHD, nor with a favourable outcome
after transplantation.
Enumeration of cytotoxic T lymphocytes precursors
(CTLp) has been shown to be related to acute GVHD
occurrence and survival by several groups (Kaminski et al,
1989; Potolicchio et al, 1996; Speiser et al, 1996; Keever-
Taylor et al, 1997). High CTLp frequencies were tightly
related to HLA class I mismatches and high HTLp
frequencies with class II mismatches (DRB1 or DPB1 alleles).
It has to be outlined that the association was made with
GVHD grade III–IV and not with grade II–IV. Grade II is
generally improved with corticosteroids but may cause
important morbidity. It seems important to try to predict
also grade II GVHD. Taken together, the data about CTLp and
HTLp frequencies are useful as functional in vitro tests,
related to HLA and non-HLA antigenic disparities. Helper T
lymphocytes act in the afferent branch of GVHD and
cytotoxic T lymphocytes in the efferent branch (Theobald,
1995).
Investigations were made to assess stimulating capacity of
patient’s PBMNC by analysing HLA-DR and CD80 expression
by flow cytometry. These two molecules are essential for
antigen presentation and T-cell stimulation. CD80 and CD87
have been shown to be essential for the development of in
vitro allogeneic T-cell responses (Knulst et al, 1994; Van Gool
et al, 1994; Gribben et al, 1996). These two molecules being
highly inducible on lymphocytes by antigenic or lymphokine
stimulation, the question was whether their expression level
could influence IL-2 secretion revealed by the HTLp test.
None of these parameters was related to pretransplant HTLp
frequency. Our results show a wide range of individual HLA-
DR expression. This may be explained by the lymphocyte to
monocyte ratio, which was low in some samples. CD80
expression was low, as expected for resting lymphocytes.
These observations allowed us to consider our samples as
homogenous regarding allogeneic stimulating capacity, and
the elevated values for HTLp were therefore due to true
antigenic stimulation. CD80 and HLA-DR expression as
assayed here will evaluate the sample as a whole and will
miss infrequent cells which express these molecules strongly.
The lack of correlation of expression in the whole sample
with HTLp frequency does therefore not mean that there
would be no correlation with CD80 and HLA-DR expression
by a rare population of stimulating cells.
In conclusion, we confirm that the HTLp test is a suitable
tool to detect antigenic differences between HLA-matched
donor and patient. It may help in donor selection and
prophylactic strategy because it is useful in detecting high
risk patients for acute GVHD and post-transplant mortality.
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